Identification by a Differential Proteomic Approach of Heat Shock Protein 27 as a Potential Marker of Atherosclerosis

Jose Luis Martin-Ventura, PhD*; Mari Carmen Duran, BSc*; Luis Miguel Blanco-Colio, PhD; Olivier Meilhac, PhD; Anne Leclercq, BSc; Jean-Baptiste Michel, MD, PhD; Ole N. Jensen, PhD; Sergio Hernandez-Merida, BSc; José Tuñón, MD, PhD; Fernando Vivanco, PhD†; Jesús Egido, MD, PhD†

Background—We hypothesized that normal and pathological vessel walls display a differential pattern of secreted proteins. We have recently set up the conditions for comparing secretomes from carotid atherosclerotic plaques and control arteries using a proteomic approach to assess whether differentially secreted proteins could represent markers for atherosclerosis.

Methods and Results—Normal endartery segments and different regions of endarterectomy pieces (noncomplicated/complicated plaques) were incubated in protein-free medium, and the released proteins were analyzed by 2D electrophoresis (2-DE). Among the differently secreted proteins, we have identified heat shock protein-27 (HSP27). Surprisingly, compared with control arteries, HSP27 release was drastically decreased in atherosclerotic plaques and barely detectable in complicated plaque supernatants. HSP27 was expressed primarily by intact vascular cells of normal arteries and carotid plaques (immunohistochemistry). Plasma detection of soluble HSP27 showed that circulating HSP27 levels are significantly decreased in the blood of patients with carotid stenosis relative to healthy subjects (0.19 [0.1 to 1.95] versus 83 [71.8 to 87.8]) ng/mL, P<0.0001).

Conclusions—HSP27 secretion is decreased in complicated atherosclerotic plaques, and sHSP27 plasma levels are decreased in atherosclerotic patients compared with healthy subjects. Plasma sHSP27 levels could be a potential index of atherosclerosis, although further validation is needed in large patient cohorts. (Circulation. 2004;110:2216-2219.)

Key Words: plasma • cells • muscle, smooth • electrophoresis

Atherosclerosis is the leading cause of death in developed countries. Beyond the classic risk factors (dyslipidemias, diabetes, and hypertension), humoral markers of plaque vulnerability related primarily to inflammation (eg, high-sensitivity C-reactive protein, interleukin-6, -10, and -18, CD40L) or reflecting pathological vascular remodeling (eg, immune activation, apoptosis, extracellular matrix degradation) have recently been highlighted. Emerging noninvasive imaging techniques for assessment of subclinical atherosclerosis permit measurement of intima-media thickness or peripheral flow-mediated dilatation, which are inversely correlated with coronary artery diseases. Despite these achievements, intermediate phenotypes between risk factors and clinical complications are needed to target vulnerable patients. We hypothesized that the patterns of protein secretion are different between atherosclerotic plaques and normal endarteries. Whereas the existing markers were found by monitoring the variations of a candidate protein related to the pathology, our strategy is to compare the secretome from normal and pathological arteries using a differential proteomic approach to identify new biological markers potentially released by the arterial wall within the plasma. The incubation of complicated and noncomplicated endarterectomy samples or control endarteries in a serum-free culture medium allowed us to harvest separately the proteins released from lesioned and healthy areas. Two-dimensional electrophoresis (2-DE) enabled us to analyze these secretomes globally and to identify, among the differentially secreted proteins, heat shock protein 27 (HSP27) as a potential marker of atherosclerosis. Confirming these results, plasma HSP27 was markedly decreased in atherosclerotic patients relative to healthy subjects.

Methods

Tissue Sampling

Twenty-eight patients (carotid stenosis >70%, 21 men/7 women; age, 68±9 years; 86% hypertensive, 39% diabetic, 54% hyperlipidemic) undergoing carotid endarterectomy at our institutions were included. Informed consent was obtained before enrollment. Blood samples were collected from these patients the day of endarterectomy.
from both arteries (Figure 1, A and B). HSP27 isoforms were characterized by LC-MS/MS analysis. Signals corresponding to the peptide QLPSeSGVEIR (m/z, 578.24 [2+]) for HSP27 protein in spot 1 and QLSseSGVEIR (m/z, 538.25 [2+]) in spot 2 demonstrated that HSP27 in spot 1 was phosphorylated. These results were confirmed by IMAC and MALDI MS/MS sequencing.5,6

Western blot analysis showed that HSP27 secretion is lower in atherosclerotic plaques (femoral, F; carotid noncomplicated plaques, NCP; carotid complicated plaques, CP) compared with control arteries (mammary, M; radial, R) (Figure 1, C and D). These data were confirmed by quantitative ELISA: M, 1243 (734–1909); R, 910 (505–2508); F, 303 (138–526); NCP, 315 (119–515); CP, 33 (17–111) (Figure 1D). We tested the secretion of other HSPs and found a diminished shSP70 level in atherosclerotic samples, whereas shSP60 showed the opposite pattern (Figure 1C). Whereas HSP60/70 exhibited a diffuse trend, diminished HSP27 release was clearly correlated to the complexity of the plaque.

Plasma HSP27 Is Decreased in Atherosclerotic Patients Relative to Healthy Subjects

To confirm our hypothesis that plasma protein content can reflect arterial wall secretion, we measured shSP27 level in the plasma of patients with carotid stenosis and healthy controls. Circulating HSP27 levels were decreased 20-fold in patients with carotid atherosclerosis relative to healthy subjects (0.19 [0.1 to 1.95] versus 83 [71.8 to 87.8] ng/mL, P<0.0001) (Figure 1D).

Tissue HSP27 Immunostaining

By immunohistochemistry, we found that both human atherosclerotic plaques and mammary arteries expressed HSP27 protein. Immunostaining for HSP27 (Figure 2, A and C) and SMC-α-actin (B and D) in serial tissue sections showed that HSP27 was expressed primarily by VSMCs.8 No staining was obtained in negative controls (not shown).

Discussion

In a preliminary study, we have validated an original approach analyzing the secreted proteomes from atherosclerotic plaques and nonpathological arterial wall by 2-DE: incubation of the tissue in a serum-free medium allows the accumulation of proteins and their subsequent analysis without interference of plasma proteins.4 In the present study, using the same procedure, we have identified HSP27, for which production by the arterial wall correlates negatively with atherosclerotic plaque complexity.

HSPs are ubiquitous proteins serving as molecular chaperones, and their cytoprotective functions rely on intracellular mechanisms. HSPs can also be secreted and released into the bloodstream, where their role in this soluble form remains unknown. In cardiovascular diseases, HSP expression is modulated both at the lesion site and in plasma.9–12 HSP70 has been suggested to protect VSMCs from oxidative aggression.13 Furthermore, increased levels of SHSP70 have been correlated with decreased intima/media thickness11 and with low risk of coronary artery disease.14 HSP60 was detected in aorta and carotid arteries, correlating with atherosclerosis severity.15 Moreover, shSP60 could be a marker of atherosclerosis.9,10 To the best of our knowledge,
Figure 1. HSP27 secretion: from arterial wall to plasma. 2D gels of secretomes from control endartery (A) and complicated plaque (B). Circles show 2 spots corresponding to HSP27, corresponding to different phosphorylation states. C, Western blot for HSP27, HSP60, and HSP70 in conditioned media samples (#, subject/patient number). D, sHSP27 quantification by ELISA. Left, Conditioned media samples (HSP27 levels normalized by protein concentration; *P<0.005 M, R vs F, NCP; †P<0.0001 M, R, F, NCP vs CP). Inset, corresponding Western blot for HSP27. Right, plasma levels of atherosclerotic patients (n=28) and controls (n=12) (*P<0.0001). Boxes represent 25th and 75th percentiles; line within boxes, median. Error bars mark 10th and 90th percentile.
remodeling process is not known and requires further investigation. Our results strongly suggest that low levels of plasma HSP27 could serve as a potential marker for atherosclerosis and should be validated in larger cohorts.

**Disclosure**

The authors are named as coinventors on pending patents filed by the Fundación Jimenez Diaz that relate to the use of biomarkers on cardiovascular disease.

**Acknowledgments**

This study was supported by Pfizer-Spain, Cardiovascular Network (03/01), Fundación Española del Corazon, SAF 2001/0717, CAM 08.4/0021.1-2003, European Network (QLG1-CT-2003-01215), IN-DAS, INSERM, and the Leducq Foundation.

**References**

11. Pockley AG, Georgiades A, Thulin T, et al. Serum HSP70 levels predict intimal hyperplasia in vivo. 17 HSP27 could also interfere with the atherosclerotic inflammatory response by inhibiting nuclear factor-kB activation. Finally, HSP27 can downregulate the apoptotic signaling pathway and could thus contribute to stabilize atherosclerotic lesions. We show for the first time that HSP27 is secreted by the undiseased vascular wall and that its release markedly diminishes according to the complexity of the plaque. Although this differential secretion does not seem to be specific for a vascular territory, because both mammary and radial endarteries secrete a higher amount of HSP27 than carotid or femoral atherosclerotic endarterectomies, this possibility cannot be excluded. Moreover, whereas sHSP27 is detected in the blood of 100% of healthy individuals, sHSP27 levels were almost undetectable in a large number of atherosclerotic patients. Despite a limited number of patients analyzed in this study, the marked statistical significance confers considerable value to our findings.

The cause and the biological significance of this important diminution of plasma HSP27 in atherosclerotic patients remain to be elucidated. Whether soluble HSP27 has an atheroprotective role or whether it is the reflection of a pathological vascular
Identification by a Differential Proteomic Approach of Heat Shock Protein 27 as a Potential Marker of Atherosclerosis

Jose Luis Martin-Ventura, Mari Carmen Duran, Luis Miguel Blanco-Colio, Olivier Meilhac, Anne Leclercq, Jean-Baptiste Michel, Ole N. Jensen, Sergio Hernandez-Merida, José Tuñón, Fernando Vivanco and Jesús Egido

Circulation. 2004;110:2216-2219; originally published online July 12, 2004; doi: 10.1161/01.CIR.0000136814.87170.B1

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/110/15/2216

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/